Metharose Sugar Free Green

Methadone Hydrochloride, the active ingredient in Metharose Sugar Free Green, is an opioid agonist presented as an oral tablet for oral use. Classified as a Schedule II controlled substance, it is used in the treatment of opioid dependence and chronic pain, providing analgesia and suppressing withdrawal symptoms in adult patients.

GNH USA supplies Metharose Sugar Free Green as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards, rigorous manufacturing practices, and export regulations to ensure product integrity across global markets.

Methadone Hydrochloride is an opioid agonist used in the management of opioid dependence and chronic pain.

- Opioid dependence: reduces withdrawal symptoms and cravings, facilitating maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe persistent pain when other opioids are insufficient. - Detoxification: assists in medically supervised opioid tapering by stabilizing patients during withdrawal. - Opioid use disorder in pregnancy: used under specialist supervision to manage dependence while minimizing fetal exposure to illicit opioids.

Methadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Drowsiness: feeling of sleepiness or fatigue. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Cardiac arrhythmia: abnormal heart rhythm, including QT prolongation. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Methadone Hydrochloride, clinicians should observe several safety precautions to minimize risks. - Assess patient history: evaluate prior opioid use, respiratory conditions, and cardiac disease. - Initiate low dose: start with the smallest effective dose and titrate cautiously. - Monitor QT interval: perform ECG monitoring in patients with risk factors for prolongation. - Avoid abrupt discontinuation: taper gradually to prevent severe withdrawal. - Educate on CNS depression: advise patients not to operate machinery or drive while sedated. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Methadone Hydrochloride interacts with several medicines; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - CYP3A4 inhibitors: such as ketoconazole or erythromycin, may increase methadone levels and risk of toxicity. - CNS depressants: benzodiazepines or alcohol, can potentiate respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: rifampin or carbamazepine, may lower methadone concentrations, reducing efficacy. - QT‑prolonging drugs: certain antiarrhythmics or antipsychotics, may increase risk of cardiac arrhythmia. - Serotonergic agents: SSRIs or tramadol, could raise the chance of serotonin syndrome.